Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer

DISEASE CHARACTERISTICS:

Histologically confirmed clear cell kidney cancer, meeting 1 of the following criteria:

Measurable metastatic disease
Locally unresectable disease
No history of known brain metastases that have not been adequately treated with radiotherapy and/or surgery
Must have received ≥ 1 prior systemic therapy for metastatic or unresectable renal cell carcinoma

PATIENT CHARACTERISTICS:

Eastern Cooperative Oncology Group (ECOG) performance status 0-2
Absolute neutrophil count > 1,500/mm³
Platelet count > 100,000/mm³
Hemoglobin > 8 g/dL
Bilirubin < 1.5 times upper limit of normal (ULN)
Serum glutamic oxaloacetic transaminase(SGOT) and Serum glutamic pyruvic transaminase(SGPT) < 2.5 times ULN
Creatinine < 1.5 times ULN
No New York Heat Association grade III-IV cardiac disease
No other malignancy within the past 5 years except basal cell skin cancer, cervical carcinoma in situ, or insignificant or inactive disease
No chronic liver disease (i.e., chronic active hepatitis or cirrhosis)
No severe or uncontrolled medical disease
No gastrointestinal disease or impairment that would hinder the absorption of everolimus
No uncontrolled diabetes
No chronic renal disease
No active uncontrolled infection
No congestive heart failure
No myocardial infarction within the past 6 months

PRIOR CONCURRENT THERAPY:

See Disease Characteristics
More than 2 weeks since prior major surgery
More than 4 weeks since prior chemotherapy (6 weeks for nitrosourea or mitomycin C)
More than 4 weeks since prior immunotherapy
More than 4 weeks since other prior investigational agents
No prior radiotherapy to > 25% of bone marrow
No prior treatment with an mammalian target of rapamycin(mTOR) inhibitor
No concurrent therapeutic warfarin